Last reviewed · How we verify
NCT05520931
Pain-related Long Covid in Covid-19 Survivors
trial testing Questionnaire and register-based data assessment in COVID-19 in 600,000 participants. Status unknown.
1 July 2023
Quick facts
| Lead sponsor | Aalborg University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 600,000 |
| Start date | 3 August 2022 |
| Primary completion | 1 July 2023 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Questionnaire and register-based data assessment
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Pain, Chronic — all drugs for Pain, Chronic →
Sponsor
Aalborg University
Who can join
18 and older, any sex, with COVID-19 or Pain, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The exploratory project aims to investigate the presence of pain as a long Covid-19 symptom in previously hospitalised patients and in non-hospitalised persons previously tested positive in a PCR test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05520931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Aalborg University trials
Trials by the same sponsor.
- NCT07580989 — Network Effects of Left M1 rTMS: A TMS-EEG Study · NA · recruiting
- NCT07395882 — A New Model to Induce Itch and Inflammation · NA · not yet recruiting
- NCT07395869 — Off-set Analgesia Induced by Cold Temperature · NA · not yet recruiting
- NCT07266103 — Mechanistic Study of Personalized rTMS in Chronic Pain · NA · not yet recruiting
- NCT07373392 — Effects of LP-LDL® on Lipid Metabolism, Glycemic Control, Inflammatory Markers, and Cognitive Function in Individuals Wi · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05520931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aalborg University
- Last refreshed: 9 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing